INS and diabetes mellitus: The lack of affordability or reimbursement limitations of SMBG may impair adherence to the recommended BG test frequencies and result in not achieving the required level of efficacy and safety of insulin, which could ultimately lead to adverse outcomes for the patients and an increase in cost to the health care system due to ineffective management of diabetes.